Valuation: Crinetics Pharmaceuticals, Inc.

Market Cap 8.96B 7.76B 7.28B 6.64B 12.49B 855B 12.69B 85.69B 33.45B 428B 33.62B 32.9B 1,427B P/E 2026 *
-18.1x
P/E 2027 * -20.6x
Enterprise Value 7.92B 6.87B 6.44B 5.87B 11.04B 756B 11.22B 75.79B 29.59B 378B 29.74B 29.09B 1,262B EV / Sales 2026 *
135x
EV / Sales 2027 * 44.8x
Free-Float
98.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.02%
1 week+0.62%
Current month+1.10%
1 month+0.92%
3 months+125.29%
6 months+97.75%
Current year+81.40%
1 week 83.96
Extreme 83.96
84.71
1 month 83.47
Extreme 83.47
84.71
Current year 32.3
Extreme 32.3
84.71
1 year 28.73
Extreme 28.73
84.71
3 years 15.76
Extreme 15.76
84.71
5 years 15.23
Extreme 15.23
84.71
10 years 10.63
Extreme 10.63
84.71
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 60 2021-09-30
Chief Executive Officer 64 2008-11-30
Director of Finance/CFO 51 2025-02-27
Director TitleAgeSince
Chairman 78 2015-09-30
Director/Board Member 64 2008-10-31
Director/Board Member 61 2018-01-31
Date Insider Type Main position Quantity % Market Cap.
8/7/26 Fiscal year

Founder

39,856 0.0378%
7/2/26 Sell

Director

-3,000 0.0028%
3/12/26 Sell

Director

5,000 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%+0.62%+180.62%+411.29% 8.96B
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.72%-2.83%+33.24%+62.24% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.35%+1.35%+38.91%-20.08% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -0.59%+3.72%+65.79%+223.01% 27.54B
Weighted average by Cap. -0.40%+3.54%+54.86%+171.11%

Financials

2026 *2027 *
Net sales 58.81M 50.98M 47.79M 43.57M 81.99M 5.61B 83.3M 563M 220M 2.81B 221M 216M 9.37B 181M 157M 147M 134M 252M 17.24B 256M 1.73B 675M 8.63B 678M 664M 28.79B
Net income -507M -440M -412M -376M -707M -48.43B -719M -4.86B -1.9B -24.24B -1.91B -1.86B -80.87B -463M -402M -377M -343M -646M -44.23B -656M -4.43B -1.73B -22.14B -1.74B -1.7B -73.86B
Net Debt -1.04B -897M -841M -767M -1.44B -98.78B -1.47B -9.9B -3.87B -49.45B -3.89B -3.8B -165B -865M -750M -703M -641M -1.21B -82.57B -1.23B -8.28B -3.23B -41.33B -3.25B -3.18B -138B
Logo Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Date Price Change Volume
26-08-13 US$84.44 -0.02% 1,289,231
26-08-12 US$84.46 +0.12% 2,583,863
26-08-11 US$84.36 +0.25% 1,422,042
26-08-10 US$84.15 +0.08% 2,330,195
26-08-07 US$84.08 +0.19% 1,941,776
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
84.44USD
Average target price
85.50USD
Spread / Average Target
+1.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNX Stock